Selenoprotein S Attenuates Tumor Necrosis Factor-α-Induced Dysfunction in Endothelial Cells

Figure 7

Effect of SelS on the p38 MAPK pathway. The expression of ICAM-1 (a) and VCAM-1 (b) in cells treated with SB203580 (an inhibitor of the p38/MAPK pathway) or S2882 (an inhibitor of the NF-κB pathway), prior to 10 ng/ml TNF-α treatment, detected by the western blot. The mRNA levels of IL-6 (c) and IL-1β (d) in HUVECs treated with SB203580 or S2882 before 10 ng/ml TNF-α induction. (e) and (f) The levels of phosphorylated p38 MAPK and p38 MAPK tested in the transfected cells after 10 ng/ml TNF-α stimulation. The expression of phosphorylated c-jun and c-jun in SelS plasmid (g) or SelS siRNA (h) transfection following 10 ng/ml TNF-α treatment and determined by the western blot. The cells were transfected with pcDNA3.1-SelS recombinant plasmid or SelS siRNAs for 30 h. The dosage used for inhibitors SB203580 and S2882 was 20 μM and 10 μM, respectively. The results are representative of triplicate independent experiments and are presented as mean ± SD, (). versus control; versus empty vector; versus negative siRNA; versus TNF-α treatment. E-vector: empty vector; Pc-SelS: pcDNA3.1-SelS plasmid; Neg.RNA: negative siRNA.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)